Clinical Trials of Cancer Immunotherapies
Abstract A016: PEGylated IL-10 (pegilodecakin) induces systemic immune activation, CD8+ T-cell invigoration and polyclonal T-cell expansion in cancer patients
Martin Oft, Aung Naing, Jeffrey R. Infante, Kyriakos P. Papadopoulos, Ivan H. Chan, Cong Shen, Navneet P. Ratti, Karen A. Autio, Deborah J. Wong, Manish R. Patel, Patrick A. Ott, Gerald S. Falchook, Shubham Pant, Annie Hung, John B. Mumm, Matthew Adamow, Scott McCauley, Rakesh Verma, Phillip Wong, Peter VanVlasselaer, Joseph Leveque and Nizar M. Tannir
Martin Oft
ARMO BioSciences, Redwoood City, CA; University of Texas MD Anderson Cancer Center, Houston, TX; SCRI, Nashville, TN; START, San Antonio, TX; Memorial Sloan Kettering Cancer Center, New York, NY; UCLA, Los Angeles, CA; Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute at HealthONE, Denver, CO.
Aung Naing
ARMO BioSciences, Redwoood City, CA; University of Texas MD Anderson Cancer Center, Houston, TX; SCRI, Nashville, TN; START, San Antonio, TX; Memorial Sloan Kettering Cancer Center, New York, NY; UCLA, Los Angeles, CA; Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute at HealthONE, Denver, CO.
Jeffrey R. Infante
ARMO BioSciences, Redwoood City, CA; University of Texas MD Anderson Cancer Center, Houston, TX; SCRI, Nashville, TN; START, San Antonio, TX; Memorial Sloan Kettering Cancer Center, New York, NY; UCLA, Los Angeles, CA; Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute at HealthONE, Denver, CO.
Kyriakos P. Papadopoulos
ARMO BioSciences, Redwoood City, CA; University of Texas MD Anderson Cancer Center, Houston, TX; SCRI, Nashville, TN; START, San Antonio, TX; Memorial Sloan Kettering Cancer Center, New York, NY; UCLA, Los Angeles, CA; Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute at HealthONE, Denver, CO.
Ivan H. Chan
ARMO BioSciences, Redwoood City, CA; University of Texas MD Anderson Cancer Center, Houston, TX; SCRI, Nashville, TN; START, San Antonio, TX; Memorial Sloan Kettering Cancer Center, New York, NY; UCLA, Los Angeles, CA; Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute at HealthONE, Denver, CO.
Cong Shen
ARMO BioSciences, Redwoood City, CA; University of Texas MD Anderson Cancer Center, Houston, TX; SCRI, Nashville, TN; START, San Antonio, TX; Memorial Sloan Kettering Cancer Center, New York, NY; UCLA, Los Angeles, CA; Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute at HealthONE, Denver, CO.
Navneet P. Ratti
ARMO BioSciences, Redwoood City, CA; University of Texas MD Anderson Cancer Center, Houston, TX; SCRI, Nashville, TN; START, San Antonio, TX; Memorial Sloan Kettering Cancer Center, New York, NY; UCLA, Los Angeles, CA; Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute at HealthONE, Denver, CO.
Karen A. Autio
ARMO BioSciences, Redwoood City, CA; University of Texas MD Anderson Cancer Center, Houston, TX; SCRI, Nashville, TN; START, San Antonio, TX; Memorial Sloan Kettering Cancer Center, New York, NY; UCLA, Los Angeles, CA; Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute at HealthONE, Denver, CO.
Deborah J. Wong
ARMO BioSciences, Redwoood City, CA; University of Texas MD Anderson Cancer Center, Houston, TX; SCRI, Nashville, TN; START, San Antonio, TX; Memorial Sloan Kettering Cancer Center, New York, NY; UCLA, Los Angeles, CA; Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute at HealthONE, Denver, CO.
Manish R. Patel
ARMO BioSciences, Redwoood City, CA; University of Texas MD Anderson Cancer Center, Houston, TX; SCRI, Nashville, TN; START, San Antonio, TX; Memorial Sloan Kettering Cancer Center, New York, NY; UCLA, Los Angeles, CA; Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute at HealthONE, Denver, CO.
Patrick A. Ott
ARMO BioSciences, Redwoood City, CA; University of Texas MD Anderson Cancer Center, Houston, TX; SCRI, Nashville, TN; START, San Antonio, TX; Memorial Sloan Kettering Cancer Center, New York, NY; UCLA, Los Angeles, CA; Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute at HealthONE, Denver, CO.
Gerald S. Falchook
ARMO BioSciences, Redwoood City, CA; University of Texas MD Anderson Cancer Center, Houston, TX; SCRI, Nashville, TN; START, San Antonio, TX; Memorial Sloan Kettering Cancer Center, New York, NY; UCLA, Los Angeles, CA; Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute at HealthONE, Denver, CO.
Shubham Pant
ARMO BioSciences, Redwoood City, CA; University of Texas MD Anderson Cancer Center, Houston, TX; SCRI, Nashville, TN; START, San Antonio, TX; Memorial Sloan Kettering Cancer Center, New York, NY; UCLA, Los Angeles, CA; Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute at HealthONE, Denver, CO.
Annie Hung
ARMO BioSciences, Redwoood City, CA; University of Texas MD Anderson Cancer Center, Houston, TX; SCRI, Nashville, TN; START, San Antonio, TX; Memorial Sloan Kettering Cancer Center, New York, NY; UCLA, Los Angeles, CA; Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute at HealthONE, Denver, CO.
John B. Mumm
ARMO BioSciences, Redwoood City, CA; University of Texas MD Anderson Cancer Center, Houston, TX; SCRI, Nashville, TN; START, San Antonio, TX; Memorial Sloan Kettering Cancer Center, New York, NY; UCLA, Los Angeles, CA; Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute at HealthONE, Denver, CO.
Matthew Adamow
ARMO BioSciences, Redwoood City, CA; University of Texas MD Anderson Cancer Center, Houston, TX; SCRI, Nashville, TN; START, San Antonio, TX; Memorial Sloan Kettering Cancer Center, New York, NY; UCLA, Los Angeles, CA; Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute at HealthONE, Denver, CO.
Scott McCauley
ARMO BioSciences, Redwoood City, CA; University of Texas MD Anderson Cancer Center, Houston, TX; SCRI, Nashville, TN; START, San Antonio, TX; Memorial Sloan Kettering Cancer Center, New York, NY; UCLA, Los Angeles, CA; Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute at HealthONE, Denver, CO.
Rakesh Verma
ARMO BioSciences, Redwoood City, CA; University of Texas MD Anderson Cancer Center, Houston, TX; SCRI, Nashville, TN; START, San Antonio, TX; Memorial Sloan Kettering Cancer Center, New York, NY; UCLA, Los Angeles, CA; Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute at HealthONE, Denver, CO.
Phillip Wong
ARMO BioSciences, Redwoood City, CA; University of Texas MD Anderson Cancer Center, Houston, TX; SCRI, Nashville, TN; START, San Antonio, TX; Memorial Sloan Kettering Cancer Center, New York, NY; UCLA, Los Angeles, CA; Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute at HealthONE, Denver, CO.
Peter VanVlasselaer
ARMO BioSciences, Redwoood City, CA; University of Texas MD Anderson Cancer Center, Houston, TX; SCRI, Nashville, TN; START, San Antonio, TX; Memorial Sloan Kettering Cancer Center, New York, NY; UCLA, Los Angeles, CA; Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute at HealthONE, Denver, CO.
Joseph Leveque
ARMO BioSciences, Redwoood City, CA; University of Texas MD Anderson Cancer Center, Houston, TX; SCRI, Nashville, TN; START, San Antonio, TX; Memorial Sloan Kettering Cancer Center, New York, NY; UCLA, Los Angeles, CA; Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute at HealthONE, Denver, CO.
Nizar M. Tannir
ARMO BioSciences, Redwoood City, CA; University of Texas MD Anderson Cancer Center, Houston, TX; SCRI, Nashville, TN; START, San Antonio, TX; Memorial Sloan Kettering Cancer Center, New York, NY; UCLA, Los Angeles, CA; Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute at HealthONE, Denver, CO.
DOI: 10.1158/2326-6074.CRICIMTEATIAACR18-A016 Published February 2019

Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 7, Issue 2 Supplement, pp. A016
Published By
Print ISSN
Online ISSN
Copyright & Usage
©2019 American Association for Cancer Research.
Author Information
- Martin Oft,
- Aung Naing,
- Jeffrey R. Infante,
- Kyriakos P. Papadopoulos,
- Ivan H. Chan,
- Cong Shen,
- Navneet P. Ratti,
- Karen A. Autio,
- Deborah J. Wong,
- Manish R. Patel,
- Patrick A. Ott,
- Gerald S. Falchook,
- Shubham Pant,
- Annie Hung,
- John B. Mumm,
- Matthew Adamow,
- Scott McCauley,
- Rakesh Verma,
- Phillip Wong,
- Peter VanVlasselaer,
- Joseph Leveque, and
- Nizar M. Tannir
- ARMO BioSciences, Redwoood City, CA; University of Texas MD Anderson Cancer Center, Houston, TX; SCRI, Nashville, TN; START, San Antonio, TX; Memorial Sloan Kettering Cancer Center, New York, NY; UCLA, Los Angeles, CA; Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute at HealthONE, Denver, CO.

February 2019
Volume 7, Issue 2 Supplement
Volume 7, Issue 2 Supplement
Abstract A016: PEGylated IL-10 (pegilodecakin) induces systemic immune activation, CD8+ T-cell invigoration and polyclonal T-cell expansion in cancer patients
Martin Oft, Aung Naing, Jeffrey R. Infante, Kyriakos P. Papadopoulos, Ivan H. Chan, Cong Shen, Navneet P. Ratti, Karen A. Autio, Deborah J. Wong, Manish R. Patel, Patrick A. Ott, Gerald S. Falchook, Shubham Pant, Annie Hung, John B. Mumm, Matthew Adamow, Scott McCauley, Rakesh Verma, Phillip Wong, Peter VanVlasselaer, Joseph Leveque and Nizar M. Tannir
Cancer Immunol Res February 1 2019 (7) (2 Supplement) A016; DOI: 10.1158/2326-6074.CRICIMTEATIAACR18-A016
Abstract A016: PEGylated IL-10 (pegilodecakin) induces systemic immune activation, CD8+ T-cell invigoration and polyclonal T-cell expansion in cancer patients
Martin Oft, Aung Naing, Jeffrey R. Infante, Kyriakos P. Papadopoulos, Ivan H. Chan, Cong Shen, Navneet P. Ratti, Karen A. Autio, Deborah J. Wong, Manish R. Patel, Patrick A. Ott, Gerald S. Falchook, Shubham Pant, Annie Hung, John B. Mumm, Matthew Adamow, Scott McCauley, Rakesh Verma, Phillip Wong, Peter VanVlasselaer, Joseph Leveque and Nizar M. Tannir
Cancer Immunol Res February 1 2019 (7) (2 Supplement) A016; DOI: 10.1158/2326-6074.CRICIMTEATIAACR18-A016
Jump to section
Advertisement